KLOW Peptide Dosage — Research Context and Component Pharmacokinetics
In plain English — what the dosage record actually covers
KLOW peptide dosage cannot be stated as a single validated figure because no controlled study has determined a safe or effective dose for the four-peptide blend in humans or in any animal model. What this page covers is the research context: the vial composition that appears across independent compounders, the doses at which the individual components were studied in animal models and limited human work, the pharmacokinetic properties of each arm, and why a single co-dissolved dose cannot hold all four at matched exposures.
This is not a dose recommendation. Describing research-dose figures for individual components in their original study contexts is editorial commentary on the published literature; it is not guidance to administer any substance.
The canonical 80 mg vial composition
The most widely referenced KLOW research vial composition across independent compounders is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. At this composition:
- GHK-Cu contributes approximately 62.5% of the total mass (50 of 80 mg), making it the mass-dominant component by a substantial margin.
- BPC-157, TB-500, and KPV each contribute 10 mg (12.5% each).
This composition is not FDA-approved, pharmacopeially defined, or established by any clinical trial. It represents the de facto research-handling standard as observed across multiple compounder listings; it is not a validated dose.
The component molecular weights differ substantially: KPV 342.44 Da, GHK-Cu 402.92 Da, BPC-157 1419.53 Da, TB-500 889.02 Da. The same mass in milligrams represents very different numbers of molecules for each component — which means the 50/10/10/10 mg ratio is not a molar ratio.
KLOW peptide dosage
In the single-component research literature, dosing was conducted at species-specific and route-specific levels that differ from the canonical vial ratios and that have no validated translation to a 'KLOW dose.'
KPV was studied at 10 nM in human intestinal epithelial cell cultures (Dalmasso et al., 2008) and at 100 micromolar in mouse drinking water in DSS- and TNBS-induced colitis models [1].
GHK-Cu was studied at 1-10 nM in cell-culture validation work for its transcriptomic effects [2], and in topical formulations in placebo-controlled clinical work for skin [3]. No systemic human dosing data exists.
BPC-157 was studied in rats at 10 microg, 10 ng, or 10 pg per rat by intraperitoneal injection (Staresinic et al., 2003) [4]. The 2025 first-in-human IV pilot used 10 mg on day 1 and 20 mg on day 2 by 1-hour infusion (n=2) [5]. No validated human dose has been established.
Thymosin beta-4 (the source of the TB-500 fragment) was applied topically in rat wound models; as little as 10 pg stimulated keratinocyte migration in vitro [6]. In the dry-eye RCT it was applied topically as ophthalmic RGN-259 (dose not extracted from abstract) [11].
KLOW dosage
Because no validated KLOW dosage exists for the blend, the question 'how much KLOW' has no grounded answer from the scientific literature. What community sources circulate is derived from the individual component dose literature and from research-use convention, not from a controlled blend trial.
The pharmacokinetic mismatch is a structural problem for any co-formulated dose. BPC-157 has a very short elimination half-life (under approximately 30 minutes in the formal rodent PK study [7]); the tripeptides KPV and GHK-Cu, being smaller and more rapidly cleared, eliminate even faster. TB-500 (Ac-LKKTETQ) has not been pharmacokinetically characterized with the same precision as full-length thymosin beta-4. In a single co-dissolved vial, the four components reach peak exposure and clear at fundamentally different rates — so no single administration schedule can simultaneously sustain all four components at pharmacologically relevant concentrations at target tissues.
KLOW peptide dosage and frequency
The question of KLOW peptide dosage and frequency — how often to administer — has no validated answer from the blend literature (which does not exist). Community discussions of frequency typically extrapolate from BPC-157 research-protocol patterns, but the blend's pharmacokinetic mismatch means that a frequency that maintains BPC-157 exposure (given its very short half-life) would overdose the slower-clearing or differently-behaved components relative to their studied levels.
In rodent studies, BPC-157 was administered once daily by intraperitoneal injection [4]. Thymosin beta-4 wound-healing studies used topical and IP applications; the single dry-eye RCT used ophthalmic drops on a clinical schedule [11]. KPV was given continuously in drinking water in mouse colitis models [1]. These schedules are study-specific and cannot be combined into a meaningful 'KLOW frequency.'
For route considerations: the research-use vial is designed for subcutaneous injection (research handling). Component literature also covers topical application (GHK-Cu), oral or targeted delivery (KPV, BPC-157 in gut models), and intra-articular injection (BPC-157). Reconstituting the lyophilized blend with bacteriostatic water is the standard research-handling procedure; the reconstituted solution is typically refrigerated.
The pharmacokinetic mismatch — why one dose cannot cover all four
The pharmacokinetic mismatch within a co-formulated vial is perhaps the most practically important caveat for understanding what KLOW dosing actually achieves. Four peptides with markedly different molecular weights, clearance mechanisms, and half-lives dissolved in one vial will not behave as four simultaneous, sustained inputs into a repair cascade.
BPC-157 (1419.53 Da) has the shortest documented half-life of the four — under approximately 30 minutes in the formal rodent pharmacokinetic study [7]. The tripeptides (KPV at 342.44 Da, GHK-Cu at 402.92 Da) are far smaller and are expected to clear at least as rapidly; GHK-Cu has the added factor of the chelated copper ion and its potential participation in redox chemistry in solution. The TB-500 fragment (889.02 Da, Ac-LKKTETQ) has not been pharmacokinetically characterized to the same degree as full-length native thymosin beta-4, which further limits direct comparison.
Copper(II) in GHK-Cu also raises a theoretical stability consideration when co-dissolved with the other peptides — whether the copper participates in oxidative chemistry that could degrade the companion peptides in solution has not been formally characterized for this mixture.